The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention voted unanimously in October to approve changes to its recommendations for the measles-mumps-rubella (MMR) vaccine. The changes focus on evidence of immunity to measles and mumps, vaccination of HIV-infected people, and use of immune globulin (IG) for measles post-exposure prophylaxis.

AAP News photo by Jeff Knox

Changes to recommendations for the measles-mumps-rubella vaccine focus on evidence of immunity to measles and mumps, vaccination of HIV- infected people and use of immune globulin for measles post-exposure prophylaxis.

The provisional ACIP recommendations will be available at www.cdc.gov/vaccines/recs/provisional/default.htm#acip.

The criteria for evidence of immunity to measles and mumps for children and adults include the following changes:

The recommendations for vaccination of HIV-infected people were revised to simplify language (remove symptomatic and asymptomatic), to recommend that the second dose of MMR vaccine be given routinely at 4 to 6...

You do not currently have access to this content.